WealthCare Investment Partners’s ImmunityBio IBRX Stock Holding History

WealthCare Investment Partners’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$146K	Buy	16,710 +200	+1%	+$1.51K	0.04%	203
2026 Q1	$133K	Hold	16,510	–	–	0.04%	190
2025 Q4	$33.4K	Hold	16,510	–	–	0.01%	183
2025 Q3	$40.9K	Hold	16,510	–	–	0.01%	171
2025 Q2	$44.9K	Hold	16,510	–	–	0.02%	157
2025 Q1	$41.4K	Hold	16,510	–	–	0.02%	148
2024 Q4	$42.4K	Hold	16,510	–	–	0.02%	146
2024 Q3	$57.6K	Hold	16,510	–	–	0.03%	140
2024 Q2	$104K	Hold	16,510	–	–	0.05%	136
2024 Q1	$88.7K	Hold	16,510	–	–	0.04%	130
2023 Q4	$73.8K	Hold	16,510	–	–	0.04%	130
2023 Q3	$25.3K	Hold	16,510	–	–	0.02%	120
2023 Q2	$44.9K	Hold	16,510	–	–	0.03%	118
2023 Q1	$30K	Hold	16,510	–	–	0.02%	128
2022 Q4	$83.7K	Buy	+16,510	New	+$90.7K	0.06%	112

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WealthCare Investment Partners's IBRX Position: Q2 2026 in Review

WealthCare Investment Partners increased its ImmunityBio (IBRX) stake by 1.2% in Q2 2026, buying an estimated $1.51K and bringing the position to 16,710 shares worth $146K. The position accounts for 0.04% of the portfolio, ranked #203.

WealthCare Investment Partners first reported a position in IBRX in Q4 2022 and has held it in 15 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

WealthCare Investment Partners held 16,710 shares of ImmunityBio worth $146K as of Q2 2026.
WealthCare Investment Partners bought 200 ImmunityBio shares in Q2 2026, an estimated $1.51K.
ImmunityBio made up 0.04% of WealthCare Investment Partners's portfolio in Q2 2026, its #203 holding.
WealthCare Investment Partners first reported a position in ImmunityBio in Q4 2022 and has held it in 15 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on WealthCare Investment Partners's 13F filing for Q2 2026, filed 10 Aug 2026.